European Urology Oncology

Slides:

Advertisements

Similar presentations

European Urology Focus

Advertisements

Volume 56, Issue 5, Pages (November 2009)

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.

Volume 71, Issue 6, Pages (June 2017)

Volume 69, Issue 3, Pages (March 2016)

Volume 59, Issue 1, Pages (January 2011)

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 72, Issue 6, Pages (December 2017)

Volume 53, Issue 4, Pages (April 2008)

Volume 61, Issue 5, Pages (May 2012)

European Urology Oncology

Volume 65, Issue 6, Pages (June 2014)

Volume 61, Issue 3, Pages (March 2012)

Volume 66, Issue 1, Pages (July 2014)

Volume 67, Issue 2, Pages (February 2015)

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 69, Issue 3, Pages (March 2016)

European Urology Oncology

Towards Early and More Specific Diagnosis of Prostate Cancer

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.

Prostate Cancer Detection: A View of the Future

Diagnostic Strategies for Prostate Cancer

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 63, Issue 6, Pages (June 2013)

Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions Anwar R. Padhani, Jeffrey Weinreb, Andrew.

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Volume 53, Issue 4, Pages (April 2008)

Volume 74, Issue 2, Pages (August 2018)

Volume 65, Issue 6, Pages (June 2014)

Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer Valeria.

Volume 67, Issue 6, Pages (June 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Volume 66, Issue 3, Pages (September 2014)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

European Urology Oncology

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

European Urology Oncology

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Volume 59, Issue 4, Pages (April 2011)

Volume 73, Issue 1, Pages (January 2018)

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

European Urology Oncology

Volume 65, Issue 3, Pages (March 2014)

Volume 75, Issue 4, Pages (April 2019)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel.

Volume 74, Issue 6, Pages (December 2018)

Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis Joseph Sargon Joseph, Vincent.

European Urology Oncology

Volume 54, Issue 5, Pages (November 2008)

The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy Neal Patel, Eliza Cricco-Lizza,

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

European Urology Oncology

Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 74, Issue 6, Pages (December 2018)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

European Urology Oncology

European Urology Oncology

Salvage Local Treatments After Focal Therapy for Prostate Cancer

European Urology Oncology

European Urology Oncology

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

European Urology Oncology

Presentation transcript:

European Urology Oncology A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging Thorgerdur Palsdottir, Tobias Nordström, Markus Aly, Fredrik Jäderling, Mark Clements, Henrik Grönberg, Martin Eklund European Urology Oncology DOI: 10.1016/j.euo.2018.09.008 Copyright © 2018 The Author(s) Terms and Conditions

Fig. 1 (A) Receiver operating characteristic (ROC) curves and (B) decision curves assessing the net benefit of risk prediction models for risk of International Society of Urological Pathology grade ≥2 prostate cancers. AUC=area under the curve, with 95% confidence interval in parentheses; PI-RADS=Prostate Imaging-Reporting and Data System; PSA=prostate-specific antigen. European Urology Oncology DOI: (10.1016/j.euo.2018.09.008) Copyright © 2018 The Author(s) Terms and Conditions

Fig. 2 Number of prostate cancers detected and biopsies performed by diagnostic strategy among 532 men who underwent prostate cancer workup in clinical practice. GG=Gleason grade group; MRI=magnetic resonance imaging; PI-RADS=Prostate Imaging-Reporting and Data System; S3M-MRI=combined risk prediction model. European Urology Oncology DOI: (10.1016/j.euo.2018.09.008) Copyright © 2018 The Author(s) Terms and Conditions